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Cancer stem cell characterization represents a breakthrough in cancer research. Despite evi-
dence showing the existence and the role of cancer stem cells in osteosarcoma (OS) onset and
progression, little is known about their specific surface phenotype. To address this issue, we
carried out a cytometric analysis with an antibody-array comprising 245 membrane proteins
comparing the stem and differentiated OS cells. As experimental model, we chose the stem-like
cell line 3aminobenzamide-OS and its parental, differentiated, cell line MG63. We identified
50 differentially expressed, 23 homogeneously expressed, and 172 not expressed proteins in
the two cell line models, thus defining a surface protein signature specific for each of them.
Furthermore, we selected ERK1/2 (p44/42 mitogen-activated protein kinases) as a potential
pathway correlated with processes that characterize tumorigenic potential and stemness of
3aminobenzamide-OS cells.
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Osteosarcoma (OS) is the most frequent nonhematologic
form of primary bone cancer in children and young adults,
accounting for about 15–20% of all bone tumors [1, 2]. It is a
devastatingmalignant neoplasmarising fromprimitive trans-
formed cells of mesenchymal origin exhibiting osteoblastic
differentiation and that produces malignant osteoids [3]. Due
to the aggressivemalignant potential and earlymetastasis, OS
is a disease with a low long-term survival rate and a poor early
diagnosis. In fact, despite important progresses in surgery,
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radiotherapy and neoadjuvant chemotherapy, the morbid-
ness of OS has been increased by 1.4% per year in the past
25 years [4, 5]. Increasing evidence suggests that tumors are
organized in a hierarchy of heterogeneous cell populations,
with the capability to sustain tumor formation and growth re-
siding specifically in a small subset of cells, that is, the cancer
stem cells (CSCs) [6–8]. These cells are endowed with both
self-renewal and multilineage differentiation potential; they
induce cell proliferation, invasion, and metastasis. Despite it
is still unclear whether a CSC originates from transformed or-
gan stem cells or whether it acquires the self-renewal capabil-
ity during tumorigenic transformation, the existence of CSC
and their role of “source” for tumor maintenance/growth is
today widely accepted. CSCs confer resistance to therapies;
thus, a successful cure of cancer should require CSCs eradica-
tion. Therefore, a number of recent studies have been focused
on CSCs existence revelation and/or on the understanding of
their features and molecular mechanisms in the attempt to
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Table 1. Surface proteins differentially expressed in 3AB-OS and
MG63 cells. Percentages of positive cells are reported for
both cell lines
Antigen Gene symbol 3AB-OS MG63
CD1b CD1b 2.0 bdl
CD10 CALLA 8.9 bdl
CD30 TNFRSF8 83.8 bdl
CD32 FCGR2A 0.7 bdl
CD49a ITGA1 67.8 bdl
CD108 SEMA7A 45.0 bdl
CD138 SDC1 78.1 bdl
CD141 THBD 14.5 bdl
CD146 MCAM 99.8 bdl
CD171 L1CAM 28.2 bdl
CD133 PROM1 71.3 bdl
CD13 ANPEP bdl 100
CD26 DPP4 bdl 5.9
CD42A GP9 bdl 13.8
CD42B GP1BA bdl 29.2
CD49B ITGA2 bdl 94.7
CD54 ICAM1 bdl 28.5
CD62E SELE bdl 3.3
CD95 FAS bdl 98.1
CD91 LRP1 bdl 22.1
CD99R MIC2 receptor bdl 4.7
CD130 IL6ST bdl 9.3
CD140A PDGFRA bdl 93.0
CD140B PDGFRB bdl 49.1
CD142 F3 bdl 1.8
CD166 ALCAM bdl 79.6
CD227 MUC1 bdl 93.3
SSEA4 SSEA4 bdl 16.8
CD243 ABCB1 2.9 4.1
CD9 CD9 80.2 99.3
CD47 CD47 24.5 98.3
CD49C ITGA3 29.0 99.7
CD51/61 CD51/61 43.9 96.5
CD55 DAF 60.7 99.8
CD61 ITGB3 1.9 53.8
CD77 A4GALT 7.9 62
CD99 MIC2 23.7 89.3
-2 microglobulin B2MICRO 10.8 98.3
EGFR EGFR 66.5 94.8
HLAABC HLAABC 35.8 99.8
CD49F ITGA6 12.2 60
CD340 ERBB2 75.1 82.3
CD221 IGF1R 39.0 77.2
CD24 CD24 13.8 5
CD97 TM7LN1 13.0 4.9
CD56 NCAM1 99.3 18.6
CD165 CD165 98.6 3.9
CD271 NGFR 84.5 12.4
MICA,MICB MICA,MICB 95.5 2.5
CD164 CD164 37.1 83.5
bdl: below detection limit.
open the way for the development of new targeted therapies
for malignant tumors [9–17].
The revelation of a subpopulation of stem-like cells in
OS dates back to 2005 by Gibbs et al. [18], after that sev-
eral research groups addressed their studies on isolation
and identification of OS stem cells using various methods
[19–24].
Recently, Di Fiore et al. induced the selection of a cancer
stem-like population from the MG63 OS cell line. This new
cell line has been named 3-aminobenzamide(AB)-OS since it
has been selected and stabilized by treating humanOSMG63
cells with 3-AB, a potent competitive inhibitor of poly(ADP-
ribose)- polymerase, for about 100 days [25].
The 3AB-OS is a stable and immortalized CSC line that
represents the stem component of MG63 parental cell line.
Differently from MG63 cells, 3AB-OS cells can grow unlim-
itedly without losing their proliferative potential [25]. They
showed a high drug efflux capacity dependent on adeno-
sine triphospate binding-cassette G2 transporters. 3AB-OS
showed a strong positivity for the stem cell marker CD133,
which was almost immeasurable in MG63 cells [25]. More-
over 3AB-OS cells were much less committed to osteogenic
and adipogenic differentiation thanMG63 cells and displayed
a high expression of the genes required for maintaining
stem cell state (Octamer-binding transcription factor 3/4, hu-
man telomerase reverse transcriptase, nucleostemin, Nanog)
and for inhibiting apoptosis (hypoxia-inducible factor-1a, B
cell lymphoma-2, and survivin) [25]. Gene expression pro-
file of 3AB-OS in comparison with MG63 revealed the dif-
ferential regulation of 196 genes involved in important path-
ways connected to tumorigenesis and stemness, namelyWnt,
Notch, Hedgehog, and extracellular signal-regulated kinase
(ERK)1/2 (p44/42 mitogen-activated protein kinases, MAPK)
signaling [26]. The 3AB-OS cells were highly tumorigenic
in mice and tumors that they formed expressed, in a first
time, high levels of pAKT, 1-integrin, and pFAK, nuclear -
catenin, c-myelocytomatosis oncogene cellular homolog, cy-
clin D2, along with high levels of anti-apoptotic proteins such
as B cell lymphoma-2 [27]. Engrafted tumor cells also showed
multilineage commitment with matrigel particularly favor-
ing the mesenchymal lineage. Concomitantly, many blood
vessels and muscle fibers appeared in the tumor mass [27].
To better characterize the biochemical phenotype of 3AB-
OS CSCs, we have analyzed their specific surface proteome
profile in comparison with the parental cell line MG63. We
performed a high-throughput immunophenotype screening
of the two cell lines using an antibody array (Lyoplate R©, Bec-
ton Dickinson, Franklin Lakes, NJ, USA) containing quite all
“cluster of differentiation” (CD) surfacemolecules along with
other surface antigens associated with stem cells phenotype
(242 different specificities),moreoverwe added an other three
antigens lacking in the original array (e.g. CD133, CD324,
CD66c). Cells were grown in DMEM supplemented with
10% FBS and 2% L-glutamine at a concentration of 20 × 103
cells/cm2.When they reached confluence, cellswere detached
from culture flasks by trypsin treatment and washed with
PBS to be stained. All primary antibodies were lyophilized
and allocated into three 96-well plates. Antibodies were re-
constituted as described by original datasheet and added to
polystyrene tubes containing 100 × 103 cells each for both
3AB-OS and MG63 cell lines. Cells were incubated for 1 h at
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Figure 1. IPA network “cell-to-
cell signalling and interaction
and inflammatory response.”
Proteins in gray were identified
in this study, proteins in white
were not identified but are re-
ported to be involved in the
network.
4C in the dark and thenwashed twicewith 500L of PBS/2%
FBS. Alexa Fluor 647-conjugated antimouse and antirat Ig
secondary antibodies were diluted as described by the pro-
ducer datasheet and added to cell pellets. Secondary antibod-
ies were incubated for 30′ at 4C in the dark . Cells were then
washed twicewith 500LofPBS/2%FBSand resuspended in
200L of PBS/2%FBS. All tubes were acquired at Beckmann
Coulter FC500 cytometer. We analyzed a total of 245 surface
specificities (Table 1 and Supporting Information Tables 1,
2, and 3) in triplicate experiments. Nine isotypic controls,
five for antimouse and four for antirat primary antibodies
(mouse IgM, IgG1, IgG2a, IgG2b, IgG3 and rat IgM, IgG1,
IgG2a, IgG2b) were included in the Lyoplate and have been
used as negative controls in the analysis. We have identi-
fied three groups of antigens: differentially expressed (50
proteins), homogeneously expressed (23 proteins), and ho-
mogeneously negative antigens (172 proteins; Supporting
Information Tables 1 and 2). Pathways and cellular func-
tions associated with differentially expressed antigens were
analyzed by ingenuity pathway analysis (IPA) software 9.0
(http://www.ingenuity.com). IPA software creates networks
of direct and indirect relationships between genes and pro-
teins on the basis of literature data. To each network IPA
associates a score computed according to Fisher’s exact test
that indicates the likelihood that interactions are random. The
parameters setting we used in our analysis has been previ-
ously described [28]. The software generated a network (score
30) related to “cell-to-cell signaling and interaction and in-
flammatory response” (Fig. 1). Interestingly several proteins
in the network were associated with tumor suppressors p21-
activated kinase and phosphatase and tensin homolog deleted
on chromosome 10 canonical pathways (Fig. 2A). The cyto-
metric dot plots of some of the differentially expressed sur-
face proteins associated with p21-activated kinase and phos-
phatase and tensin homolog deleted on chromosome 10 are
shown in Supporting Information Fig. 1.
Most of the proteins involved in the two pathways are com-
mon; particularly a central role in both signaling is played
by ERK1/2 (MAPK). MAPKs are involved in several cellu-
lar programs as cell proliferation, differentiation, motility
and cell survival. Moreover, MAPKs signaling pathway is
an important target in the diagnosis and treatment of can-
cer [29]. To confirm the involvement of MAPKs signaling
in 3AB-OS cells, we decided to investigate the level of ex-
pression of ERK1/2 (MAPK) and its phosphorylated counter-
parts by Western blotting analysis (Fig. 2B and supplemental
methods).
Our data demonstrated an activation of MAPKs pathway
in 3AB-OS cells due to the exclusive presence of the phos-
phorylated form of MAPKs in this cell line (Fig. 2B). MAPKs
pathway is involved in the cytoskeleton rearrangement dur-
ing tumoral cells invasion processes suggesting that it could
be connected to the previously observed enhanced motility
and invasiveness of 3AB-OS cancer stem-like cells [25].
Our data reveal for the first time a significant number
(245 antigens) of identified surface proteins in MG63 and
in its derived CSC line 3AB-OS, thus highlighting a surface
protein signatures specific differentiated MG63 parental cell
line and its stem-like counterpart. Moreover, we associated
the surface protein profile of 3AB-OS CSCs with MAPKs
pathway activation, the latter was already found in 3AB-OS
CSCs during transcriptome analysis performed by Di Fiore
et al. [26].
We are confident that these data will benefit further in-
vestigations regarding this newly established cell line as well
as ongoing research on OS CSCs. These findings enrich our
knowledge of the surface proteome of OS stem cell, provid-
ing preliminary information also in the development of new
C© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
3296 M. Gemei et al. Proteomics 2013, 13, 3293–3297
Figure 2. (A) PAK (p21-activated
kinase) and PTEN (phosphatase
and tensin homologue deleted
on chromosome 10) pathways.
Some of the proteins in the
network “cell-to-cell signaling
and interaction and inflamma-
tory response” are associated
with PAK (blue) and PTEN (red)
canonical pathways. Molecules
we identified differentially ex-
pressed are in green while
those in orange were added
by IPA network analysis. ERK1/2
(MAPK) is one of the central
nodes of both PAK and PTEN
pathways. (B) ERK1/2 (MAPK)
protein expression level and
phosphorylation status. West-
ern blotting analysis and densit-
ometric measurements of pro-
tein lysates of 3AB-OS and
MG63 cells. Proteins were sep-
arated on 4–15% SDS-PAGE and
immunoblottedwith specific an-
tibodies. The analyses were per-
formed on three independent
samples; the results are shown
as mean ± SD.
therapeutic approaches. In fact, surface protein profiling is a
key step in the screening for new therapeutic targets; more-
over surface antigens are suitable for cancer cell targeted
monoclonal antibodies-based therapies.
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